Case Report
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastrointest Pathophysiol. Aug 15, 2013; 4(3): 59-62
Published online Aug 15, 2013. doi: 10.4291/wjgp.v4.i3.59
Severe hemorrhagic colitis in a patient with chronic myeloid leukemia in the blastic phase after dasatinib use
Zahra Kmira, Ben Sayed Nesrine, Zaghouani Houneida, Ben Fredj Wafa, Slama Aida, Ben Youssef Yosra, Zaier Monia, Badreddine Sriha, Khelif Abderrahim
Zahra Kmira, Ben Sayed Nesrine, Ben Fredj Wafa, Ben Youssef Yosra, Zaier Monia, Khelif Abderrahim, Department of Clinical Hematology, University Hospital Farhat Hached, Sousse 4000, Tunisia
Zaghouani Houneida, Department of Radiology, University Hospital Farhat Hached, Sousse 4000, Tunisia
Slama Aida, Department of Gastroenterology, University Hospital Sahloul, Sousse 4000, Tunisia
Badreddine Sriha, Department of Anatomopathology, University Hospital Farhat Hached, Sousse 4000, Tunisia
Author contributions: All authors contributed to this work.
Correspondence to: Dr. Zahra Kmira, Department of Clinical Hematology, University Hospital Farhat Hached, Avenue Ibn Eljazzar, Sousse 4000, Tunisia. kmira_zahra@yahoo.fr
Telephone: +216-21-135521
Received: June 23, 2013
Revised: July 17, 2013
Accepted: August 4, 2013
Published online: August 15, 2013
Processing time: 46 Days and 21 Hours
Abstract

Dasatinib is a second-line tyrosine kinase inhibitor used in patients with imatinib resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute leukemia. Gastrointestinal bleeding may occur in up to 7% of patients using dasatinib, although, severe dasatinib-related acute colitis had rarely been reported. Here, we present the case of a 36-year-old female who progressed to acute myeloid leukemia after fourteen months of receiving imatinib for CML in the chronic phase and was treated with a dasatinib-containing chemotherapy regimen. On day 34 of treatment, the patient developed moderate abdominal pain and bloody diarrhea with mucous. Analyses of stool specimens were negative for parasites, Clostridium difficile, and other pathogenic bacteria. The cytomegalovirus pp65 antigen was negative in her blood leukocytes. A colonoscopy revealed acute colitis, and a mucosal biopsy showed nonspecific colitis. The patient was treated with broad-spectrum antibiotics, bowel rest and hydration, and dasatinib treatment was stopped. Her bloody diarrhea improved within 72 h. After confirming cytological remission, the patient received initial course of consolidation, and dasatinib treatment was reinstated. However, hemorrhagic colitis recurred. After discontinuing dasatinib, herhemorrhagic colitis drastically improved and did not recur following the administration of nilotinib. The characteristics of our patient suggest that dasatinib treatment can lead to hemorrhagic colitis, which typically resolves after discontinuation of the drug.

Keywords: Philadelphia chromosome; Chronic myeloid leukemia; Dasatinib; Colitis

Core tip: Dasatinib is a second-line tyrosine kinase inhibitor used in imatinib resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute leukemia patients. Dasatinib, which binds to the active and inactive conformation of the BCR-ABL oncoprotein, demonstrates greater potency than imatinib for wild-type and mutant BCR-ABL cases, with the exception of the T315I mutation. The most frequent adverse effects include myelosuppression, diarrhea, nausea and peripheral edema. Severe dasatinib-relatedacute colitis without thrombocytopenia, coagulation abnormalities or colonic ulcers has rarely been reported. Here, we report the case of an adult patient with Philadelphia chromosome positive CML in the blastic phase who developed acute colitis after dasatinib use.